Tildrakizumab
- Generic Name
- Tildrakizumab
- Brand Names
- Ilumya, Ilumetri
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1326244-10-3
- Unique Ingredient Identifier
- DEW6X41BEK
- Background
Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis .
...
- Indication
Moderate-severe plaque psoriasis , .
- Associated Conditions
- Moderate to Severe Plaque Psoriasis
- Associated Therapies
- -
A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 50
- Registration Number
- NCT06488170
- Locations
- 🇨🇿
University Hospital Ostrava, Ostrava, Czechia
🇨🇿Fakultní nemocnice Plzeň, with its registred seat at Edvarda Beneše, Pilsen, Czechia
🇨🇿University Hospital in Motol, Praha, Czechia
A Study of Tildrakizumab in the Treatment of Genital Psoriasis (CZATCH-Genital-PsO)
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 110
- Registration Number
- NCT06029257
- Locations
- 🇦🇹
Medizinische Universität Graz, Graz, Styria, Austria
A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 50
- Registration Number
- NCT06030076
- Locations
- 🇦🇹
Gesundheitszentrum Citypark Graz, Graz, Styria, Austria
Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo
- Conditions
- Interventions
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Premier Specialists, Australia
- Target Recruit Count
- 12
- Registration Number
- NCT04971200
- Locations
- 🇦🇺
Premier Specialists Pty Ltd, Sydney, New South Wales, Australia
Observational Real-world Evidence (RWE) Study to Assess Patient-reported Wellbeing Using Tildrakizumab in Live Setting - POSITIVE Study
- First Posted Date
- 2021-03-30
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 782
- Registration Number
- NCT04823247
- Locations
- 🇩🇪
Haut- und Laserzentrum Freising, Freising, Bavaria, Germany
Abiraterone Acetate in Combination With Tildrakizumab
- Conditions
- Interventions
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Target Recruit Count
- 13
- Registration Number
- NCT04458311
- Locations
- 🇬🇧
Belfast City Hospital, Belfast, UK, United Kingdom
🇬🇧Cancer Research Centre at Weston Park Hospital, Sheffield, England, United Kingdom
🇬🇧The Royal Marsden Hospital Foundation Trust, Sutton, UK, United Kingdom
Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 244
- Registration Number
- NCT04340076
- Locations
- 🇳🇱
Amphia Hospital, Breda, Netherlands
🇳🇱Radboudumc, Nijmegen, Netherlands
🇳🇱Máxima Medisch Centrum, Veldhoven, Netherlands
MIcrovascular dysfuNction In Moderate-severe Psoriasis
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Marcelo F. Di Carli, MD, FACC
- Target Recruit Count
- 36
- Registration Number
- NCT04271540
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy
- Conditions
- Interventions
- First Posted Date
- 2020-02-11
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 190
- Registration Number
- NCT04263610
- Locations
- 🇩🇪
Investigator Site 3, Augsburg, Germany
🇬🇧Investigator Site 2, London, United Kingdom
🇬🇧Investigator Site 1, Bristol, United Kingdom
Observational Study of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice
- First Posted Date
- 2019-12-18
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 331
- Registration Number
- NCT04203693
- Locations
- 🇳🇱
Investigational site 1, Breda, Netherlands
🇮🇹Investigational site 5, Roma, Italy
🇩🇪Investigational site 13, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.